dQ&A's latest diabetes research includes two presentations from our team at ATTD 2026, one of the world's leading stages for diabetes advancements.
Our survey of 190 U.S. endocrinologists finds GLP-1 and SGLT2 prescribing at 90%+ and rising, while many patients resist starting basal insulin.
A dQ&A-CeQur study in Clinical Diabetes finds 2 months on the CeQur Simplicity insulin patch boosts patient satisfaction, cuts burden, and lifts well-being.
This article reports results of a survey of patients and health care providers regarding their experiences of and challenges with the use of basal insulin.
dQ&A research reveals primary care challenges in adopting diabetes tech, highlighting needs for CGM training, simpler tools, and better industry support.
Our research finds Mounjaro patients report health benefits but face confusion and frustration during therapy initiation.
Our European study explores Time in Range in diabetes, comparing outcomes and differences across six countries.
Philly De Piante recently presented dQ&A data on Advances in Disease-Modifying Interventions at the Global Congress on Cardiology. Watch the video here.
We are excited to announce that the dQ&A team presented eight abstracts at the Advanced Technologies and Treatments for Diabetes (ATTD) 2023 conference.
